Impact of polypharmacy and aging on the risk of multiple drug-drug interactions (DDIs) in HCV patients treated with pangenotypic direct-acting antivirals (pDAA)

M Andretta,D Re,P Toniutto,F.V Rizzi,G.A Nieto,V Perrone,F Ferrante,L Degli Esposti,A Lupi,S Fagiuoli,N Coppola,A Mangia,D.D Ancona,S Palcic,F Bartolini,C Hernandez

doi:10.1016/j.dld.2022.01.087

Abstract

Background: Recent studies suggest that sofosbuvir-based regimens are preferred in HCV elderly patients for their slightly more user-friendly DDI profile compared to protease inhibitor-based regimens. Our aim was to explore the impact of polymedication and aging on multiple DDIs prevalence in patients treated with sofosbuvir/velpatasvir (SOF/VEL) or glecaprevir/pibrentasvir (GLE/PIB).

Full Text